Search Medical Condition
Please enter condition
Please choose location from dropdown

Salem, Virginia Clinical Trials

A listing of Salem, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (112) clinical trials

Prospective Thinking in Hormone-Responsive Breast Cancer

Globally, breast cancer is the most common cause of cancer death among women. The most common pathological subtype is hormone receptor positive breast cancer, which accounts for approximately 70% of all diagnoses. Adherence to adjuvant hormone therapy (HT), including selective estrogen receptor modulators and aromatase inhibitors, in the treatment of ...

Phase N/A

6.44 miles

Learn More »

Testing the Neuroscience of Guided Learning in Depression

Major depressive disorder ranks among the most significant causes of mortality and disability in the world. Recent data from the investigators and others highlight that impairments in reward and loss learning are central to depression, have distinct neural substrates, and improve with successful treatment. Together, these findings suggest an urgent ...

Phase N/A

6.44 miles

Learn More »

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. Estimate the probability of a dose limiting toxicity (DLT) following cycle 1 of experimental regimens (pegylated liposomal doxorubicin hydrochloride [pegylated liposomal doxorubicin] [PLD] and atezolizumab and PLD/bevacizumab and atezolizumab). (Safety lead-in) II. Estimate and compare the hazard of first progression or death (progression free survival [PFS]) of ...

Phase

6.44 miles

Learn More »

Clinical Trial Evaluating the Effect of Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

This study is a prospective, multi-center, RCT designed to collect patient outcome data on two commercially available SOC treatments for DFUs. The trial will be single blinded in regard to wound healing assessment (another clinician, other than the investigator at each site will assess wound healing) and confirmation of wound ...

Phase N/A

6.44 miles

Learn More »

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

Phase

6.44 miles

Learn More »

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Phase

6.44 miles

Learn More »

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.

Phase

6.44 miles

Learn More »

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Phase

6.44 miles

Learn More »

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Phase

6.44 miles

Learn More »

COMET Study 1: Filter Ventilated Cigarette Substitution in the ETM

The duration of the experiment will be approximately 3 months. Participants will begin with an initial one week (approximately) exposure period to both unventilated and ventilated cigarettes as well as alternative nicotine products (e-cigarettes, snus, etc.) that will be made available throughout the experiment. Participants will be given the opportunity ...

Phase N/A

6.44 miles

Learn More »